gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## Cais Rhyddid Gwybodaeth / Freedom of Information request Ein Cyf / Our Ref: 23-E-010

Please note that we have provided this information for the period September 2022 to February 2023.

## You asked:

## How many patients has your health board treated in the past 6 months (for any disease) with the following drugs:

- Aubagio (teriflunomide) 0
- Avonex (interferon beta-1a) 8
- Betaferon (interferon beta-1b) <5\*
- Brabio (glatiramer acetate) 0
- Copaxone (glatiramer acetate) 29
- Extavia (beta interferon-1b) 0
- Gilenya (fingolimod) 15
- Lemtrada (alemtuzumab) 0
- Kesimpta (ofatumumab) 60
- Mavenclad (cladribine) 8
- Mayzent (siponimod) 28
- Ocrevus (ocrelizumab) 189
- Plegridy (peginterferon beta-1a) 30
- Ponvory (ponesimod) 0
- Rebif (beta interferon-1a) 7
- Tecfidera (dimethyl fumarate) 44
- Tysabri (natalizumab) 91
- Tysabri (natalizumab) pre-filled syringes ONLY 428
- Vumerity (diroximel fumarate) 0
- Zeposia (ozanimod) 0



It would also be very helpful if you could advise how many hospital patients registered with your health board have a primary or secondary diagnosis for the the following conditions:

Please note that we have provided the number of patients who have been admitted in the specified time period who had a diagnosis of Multiple Sclerosis on their record at any point during the admision. We are not able to break this down by type of Multiple Sclerosis.

350 patients were admitted in the period September 2022 to February 2023 with a diagnosis of Multiple Sclerosis on their inpatient record.

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.